Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY24 results · Jul–Sep 2023
Solara Active Pharma Sciences reported revenue from operations of ₹425.24 crore (up 25.7% from Q2 FY23) and net loss of ₹17.06 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 425.24 | 338.37 | +25.7% | 352.31 | +20.7% |
| Other income | 1.18 | 3.72 | −68.3% | 2.04 | −42.2% |
| Total income | 426.42 | 342.09 | +24.7% | 354.35 | +20.3% |
| Profit before tax | (17.06) | (19.30) | Loss narrowed | (29.36) | Loss narrowed |
| Net profit for the period | (17.06) | (9.98) | Loss widened | (19.11) | Loss narrowed |
| Attributable to shareholders of the company | (17.16) | (9.96) | Loss widened | (19.55) | Loss narrowed |
| EPS, basic (₹) | (4.77) | (2.77) | Loss widened | (5.43) | Loss narrowed |
| Net margin (%) | -4.0 | -2.9 | -5.4 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 425.24 | 338.37 | +25.7% | 352.31 | +20.7% |
| Other income | 1.23 | 3.77 | −67.4% | 2.07 | −40.6% |
| Total income | 426.47 | 342.14 | +24.6% | 354.38 | +20.3% |
| Profit before tax | (15.26) | (19.23) | Loss narrowed | (30.13) | Loss narrowed |
| Net profit for the period | (15.26) | (9.91) | Loss widened | (19.88) | Loss narrowed |
| EPS, basic (₹) | (4.24) | (2.75) | Loss widened | (5.52) | Loss narrowed |
| Net margin (%) | -3.6 | -2.9 | -5.6 |
Consolidated
- Filed with BSE
- 24 Nov 2023, 12:23 IST
- Board meeting
- 14 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Nov 2023, 12:23 IST
- Board meeting
- 14 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE